Shih W J, Rastogi A, Stipp V, Gross K K, Coupal J J, Magoun S
Nuclear Medicine Service, VA Medical Center and University of Kentucky Medical Center, Lexington 40511, USA.
Clin Nucl Med. 1998 Sep;23(9):594-600. doi: 10.1097/00003072-199809000-00007.
Thirty-one men (age range, 46-76 years; mean age, 64.8 years) with intrathoracic masses suggesting possible malignancy on the basis of chest radiography or CT underwent preoperative Tc-99m MIBI SPECT examinations. Diagnosis was confirmed on pathologic examinations of samples obtained either at thoracotomy, esophagectomy, or by biopsy. Twenty-five patients had primary lung cancer, including squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and small cell carcinoma. Two patients had lymphomas with spread to the mediastinum, and three patients had extrathoracic primary cancers (one squamous cell carcinoma of esophagus, one squamous cell carcinoma originating from a head and neck tumor, and one metastatic mediastinal leiomyosarcoma). One patient with a tuberculoma had negative results of the Tc-99m MIBI examination. Tc-99m MIBI had a 86.7% sensitivity rate, a 0% false-positive rate, and a 100% positive predictive value to detect malignant intrathoracic masses. There was a 13% false-negative rate, however, suggesting that MIBI-SPECT may underdiagnose malignant lesions. SPECT findings of these 31 patients can be classified as 1) mass with increased uptake, n = 23; 2) ring-like appearance of increased uptake, n = 3; 3) mass with absent uptake, n = 4; and 4) photon-deficient mass, n = 1. Absent uptake in patients with mass lesions could be explained by necrosis of the lesion (caseation necrosis or massive tumor necrosis with or without bleeding). Most malignant intrathoracic masses are Tc-99m MIBI avid and may be detected with a high degree of sensitivity and with an excellent positive predictive value. A positive MIBI scan may help in the clinical diagnosis of malignancy. The use of Tc-99m MIBI could serve not only as a tumor imaging agent, but also may be used to determine the extent of spread and potentially the chemotherapeutic responsiveness of a tumor.
31名男性(年龄范围46 - 76岁;平均年龄64.8岁),其胸部X线或CT显示胸腔内有提示可能为恶性的肿块,术前行99mTc-MIBI SPECT检查。通过开胸手术、食管切除术或活检获取的样本进行病理检查确诊。25例患者患有原发性肺癌,包括鳞状细胞癌、大细胞癌、腺癌和小细胞癌。2例患者患有淋巴瘤并累及纵隔,3例患者患有胸外原发性癌症(1例食管鳞状细胞癌、1例起源于头颈部肿瘤的鳞状细胞癌和1例转移性纵隔平滑肌肉瘤)。1例患有结核瘤的患者99mTc-MIBI检查结果为阴性。99mTc-MIBI检测胸腔内恶性肿块的灵敏度为86.7%,假阳性率为0%,阳性预测值为100%。然而,假阴性率为13%,提示MIBI-SPECT可能会漏诊恶性病变。这31例患者的SPECT表现可分为:1)摄取增加的肿块,n = 23;2)摄取增加的环状表现,n = 3;3)无摄取的肿块,n = 4;4)光子缺乏性肿块,n = 1。肿块病变患者无摄取可能是由于病变坏死(干酪样坏死或伴有或不伴有出血的大量肿瘤坏死)。大多数胸腔内恶性肿块对99mTc-MIBI摄取良好,可通过高灵敏度和出色的阳性预测值检测到。MIBI扫描阳性可能有助于恶性肿瘤的临床诊断。99mTc-MIBI不仅可作为肿瘤显像剂,还可用于确定肿瘤的扩散范围以及潜在的化疗反应性。